Special Issue "Molecular Pathology of Triple-Negative Breast Cancer and Therapeutic Implications"
Deadline for manuscript submissions: closed (30 September 2021).
Interests: cancer signaling; cell cycle; breast cancer; centrosome; mitosis; racial disparity; anticancer agents
Triple-negative breast cancers (TNBCs) are known by what they lack, rather than what they have. Unfortunately, what is “missing” is not actionable. Unsurprisingly, they are the most aggressive subtype of breast cancer, characterized by worse prognosis, higher propensity to earlier metastases, and shorter survival after recurrence relative to other breast cancer subtypes. The clinical and molecular heterogeneity of TNBC is well known. Over these years, our knowledge about the molecular subtypes of TNBC has increased significantly; however, there is still a long way to go before we have deciphered the actionable biology in TNBC.
In the TNBC landscape, research gaps remain in the understanding of: (1) prognostic and predictive biomarkers, as well as druggable targets, given substantial differences between the various subtypes of TNBC; (2) the role of the tumor microenvironment in driving tumor progression and therapy resistance; (3) research related to social epigenomics; and (4) race in preclinical studies and drivers of disease progression.
In this Special Issue of IJMS, we aim to stimulate discussions that span the complexly intertwined multiple domains of influence (biological, racial, behavioral, and sociocultural) by bringing together expert opinions and new advances from across the field. We welcome the submission of research and review articles on aspects that contribute to mechanisms of TNBC progression, relapse, and therapy resistance using multi-omics approaches. We also welcome submissions that cover any relevant topic, including the role of androgen receptor, hypoxia, immune microenvironment, racial disparities, and obesity in TNBC progression, as well as new therapeutic approaches.
Dr. Ritu Aneja
Dr. Karuna Mittal
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- prognostic and predictive biomarkers
- immune microenvironment
- racial disparity
- androgen receptor
- social epigenomics
- molecular subtypes
- machine learning